Ratiu Ileana Andreea, Ligor Tomasz, Bocos-Bintintan Victor, Mayhew Chris A, Buszewski Bogusław
Interdisciplinary Centre of Modern Technologies, Nicolaus Copernicus University, 87-100 Toruń, Poland.
Department of Environmental Chemistry and Bioanalytics, Faculty of Chemistry, Nicolaus Copernicus University, 87-100 Toruń, Poland.
J Clin Med. 2020 Dec 24;10(1):32. doi: 10.3390/jcm10010032.
Lung cancer, chronic obstructive pulmonary disease (COPD) and asthma are inflammatory diseases that have risen worldwide, posing a major public health issue, encompassing not only physical and psychological morbidity and mortality, but also incurring significant societal costs. The leading cause of death worldwide by cancer is that of the lung, which, in large part, is a result of the disease often not being detected until a late stage. Although COPD and asthma are conditions with considerably lower mortality, they are extremely distressful to people and involve high healthcare overheads. Moreover, for these diseases, diagnostic methods are not only costly but are also invasive, thereby adding to people's stress. It has been appreciated for many decades that the analysis of trace volatile organic compounds (VOCs) in exhaled breath could potentially provide cheaper, rapid, and non-invasive screening procedures to diagnose and monitor the above diseases of the lung. However, after decades of research associated with breath biomarker discovery, no breath VOC tests are clinically available. Reasons for this include the little consensus as to which breath volatiles (or pattern of volatiles) can be used to discriminate people with lung diseases, and our limited understanding of the biological origin of the identified VOCs. Lung disease diagnosis using breath VOCs is challenging. Nevertheless, the numerous studies of breath volatiles and lung disease provide guidance as to what volatiles need further investigation for use in differential diagnosis, highlight the urgent need for non-invasive clinical breath tests, illustrate the way forward for future studies, and provide significant guidance to achieve the goal of developing non-invasive diagnostic tests for lung disease. This review provides an overview of these issues from evaluating key studies that have been undertaken in the years 2010-2019, in order to present objective and comprehensive updated information that presents the progress that has been made in this field. The potential of this approach is highlighted, while strengths, weaknesses, opportunities, and threats are discussed. This review will be of interest to chemists, biologists, medical doctors and researchers involved in the development of analytical instruments for breath diagnosis.
肺癌、慢性阻塞性肺疾病(COPD)和哮喘是在全球范围内发病率不断上升的炎症性疾病,构成了一个重大的公共卫生问题,不仅涉及身体和心理方面的发病和死亡,还产生了巨大的社会成本。全球范围内癌症导致的主要死因是肺癌,这在很大程度上是由于该疾病往往直到晚期才被发现。尽管慢性阻塞性肺疾病和哮喘的死亡率相对较低,但它们给患者带来极大痛苦,且涉及高昂的医疗费用。此外,对于这些疾病,诊断方法不仅成本高昂,而且具有侵入性,这进一步增加了患者的压力。几十年来,人们已经认识到分析呼出气体中的痕量挥发性有机化合物(VOCs)有可能提供更便宜、快速且非侵入性的筛查程序,用于诊断和监测上述肺部疾病。然而,经过数十年与呼出气体生物标志物发现相关的研究,目前尚无临床可用的呼出气体VOC检测方法。原因包括对于哪些呼出气体挥发性物质(或挥发性物质模式)可用于区分肺部疾病患者缺乏共识,以及我们对已鉴定出的VOCs的生物学来源了解有限。利用呼出气体VOCs进行肺部疾病诊断具有挑战性。尽管如此,众多关于呼出气体挥发性物质与肺部疾病的研究为哪些挥发性物质需要进一步研究以用于鉴别诊断提供了指导,凸显了对非侵入性临床呼出气体检测的迫切需求,阐明了未来研究的方向,并为实现开发肺部疾病非侵入性诊断测试的目标提供了重要指导。本综述通过评估2010年至2019年间开展的关键研究,对这些问题进行了概述,以便提供客观、全面的最新信息,展示该领域取得的进展。文中强调了这种方法的潜力,同时讨论了其优势、劣势、机遇和挑战。本综述将对参与呼出气体诊断分析仪器开发的化学家、生物学家、医生和研究人员具有参考价值。